Alamar Biosciences 與多間頂尖研究大學合作啟動全國計劃，旨在推動神經退行性疾病相關的血漿生物標記研究

Alamar Biosciences announced a national-scale proteomics initiative in collaboration with Washington University, University of Wisconsin, and Indiana University to analyze approximately 21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using its NULISAseq Neuro 220 multiplex panel. The resulting open-access dataset will be linked to the National Alzheimer's Coordinating Center and will support AI-driven biomarker discovery and validation for neurodegenerative diseases.